search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
HEAL ▶▶▶TH


Treating E. coli in the era of prudent use


In a world where antibiotics use in livestock is increasingly under scrutiny, it is becoming vital to exactly understand the mode of action of each antibiotic. That will allow swine veterinarians to know in detail when to apply them and in which manner – making sure the best outcome is guaranteed for both the pigs and their environments.


BY ULRICH KLEIN, DVM, GLOBAL PRODUCT MANAGER THERAPEUTICS, HUVEPHARMA E Antibiotics


Apramycin* (8mg/kg bw) feed medication


Paromomycin** (25mg/kg bw) water medication


scherichia coli is a gram-negative bacterium which is the causative agent of pig neonatal diarrhoea and post-weaning diarrhoea. Both diseases are life- threatening and are important causes of economic


losses for the pig industry due to mortality, morbidity and de- creased growth rate. Antimicrobial therapy in cases of enteric colibacillosis infec- tions is still based on the use of various classes of anti- biotics. New regulations limit the use of different antibiotic classes for E. coli treatment. Implementation of an antibiotic


Table 1 - Apramycin* and paromomycin** concentrations in small and large intestine content during feed and water medication and after medication cessation.


Day of treatment/ hours post treatment


Day 21 of treatment


12 hours after treatment stop


Day 5 of treatment


24 hours after treatment stop


* Apravet, Huvepharma ** Parofor, Huvepharma


10 ▶ PIG PROGRESS | Volume 37, No. 7, 2021


Small intestine (μg/g)


45.0 33.2 760.3 17.6


Large intestine (μg/g)


88.2 54.0 640.5 71.0


categorisation system in the EU in February 2023 will re- strict the use of several antibiotics that are considered criti- cally important for human medicine; think of colistin, dano- floxacin and enrofloxacin. Zinc oxide as a therapeutic drug (2,000–3,000 ppm) will be banned for medical use in June 2022 and already is not mark- eted anymore in a range of European countries: Belgium, France, the Netherlands and Germany. Missing cross-protec- tion and a narrow activity spectrum impede the effective use of vaccines as a preventive approach to manage colibacillosis infections. That necessitates the use of other effective coli- bacillosis antibiotic treatment options – ideally those which are not classed as critically important for humans.


Antibiotic stewardship and requirements Antibiotic stewardship requires professional veterinarians to abide by certain requirements. A vet should sustain the effi- cacy of antibiotics and prevent resistance development. In addition, a veterinarian should optimise dosing based on im- proved understanding of the mode of action of antimicrobial products. Thirdly, a vet should use the most effective anti- biotic for treatment purposes. Successful treatment of E. coli infections can only be achieved by the administration of an antibiotic that reaches therapeu- tic concentrations at the intestinal infection site, where E. coli is present. The antimicrobial susceptibility of E. coli strains is fundamental to combat the emergence and expansion of antibacterial resistance. When choosing antibiotics, a veterinarian should consider: • Antibiotic therapeutic concentrations in the intestine; and • The sensitivity of E. coli strains, which is why susceptibility testing is fundamental for correct therapy. Responsible use of antibiotics in animals lowers the risk of bacteria becoming resistant. A key element in veterinary practice is prudent antibiotic use based on pharmacokinetic (PK) and pharmacodynamic (PD) data. The decision to treat and the choice of antibiotics is ideally based on PK/PD knowledge, which is in line with global treatment guidelines in place on antibiotic usage.


E. coli treatment options Apravet (apramycin) and Parofor (paromomycin), both marketed by Huvepharma, belong to the group of


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44